Submit your article by clicking on the button below
Our Journal makes a plagiarism checker by a certificate program.
Instructions for Authors
CellR4 publishes Editorials, Reviews, Original Papers, and Scientific Correspondence/Letters on subjects regarding cellular repair, replacement, regeneration and reprogramming, from basic science to translational research and clinical trials. CellR4 is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety, and meta-analyses. Reviews should include systematic revision of the literature concerning the treated topics and preferably meta-analyses, original illustration, and tables.
CellR4 is also the official journal of The Cure Alliance (www.thecurealliance.org), a no-profit international organization that includes physicians, scientists, business and philanthropy leaders, with the mission to promote the development of novel treatments for diseases now afflicting humankind, through collaborative efforts worldwide, while addressing and overcoming impediments to the development of cures. In this direction, CellR4 will also serve as a shared platform for communicating and debating challenges and opportunities on the path to the development of new treatments. Many of these topics are shared by most translational efforts in the fields of cell therapy and regenerative medicine, independently from the specific disease areas. CellR4 will, thus, also publish original articles, reviews and commentaries/opinion papers on regulatory, legal, and ethical issues, as well as publish information on global collaborative platforms and funding opportunities of interest.
CellR4 doesn’t accept publication of language referring to “data not shown” or “unpublished data”. Letters are restricted to the discussion of papers already published in the journal, with a maximum of 300 words, one table or figure and up to ten references.
Short Reports and Case Reports will be considered for publication only if of particular interest. The structured abstract must not exceed 200 words.
Please read and apply the loading instructions given at this site, noting that all information entered during the submission process related to the manuscript should also be included, and be identical to the final submitted version of the manuscript – please see full details under “Presentation of Manuscripts”. Papers must be submitted exclusively to the Journal, and are accepted on the understanding that they have not been, and will not be, published elsewhere. The correspondence for each article must be followed only by the corresponding author. The submission process requires a full declaration of personal interests of all Authors and funding interests; these details should also be included in the text of the manuscript (see below).
Please note that the journal employs a plagiarism detection system. By submitting your manuscript to the journal you accept that your manuscript may be screened for plagiarism against previously published work.
Authors must fulfill the following criteria:
He/she must have made a substantial contribution to research design, or to the acquisition, analysis or interpretation of data;
He/she must have drafted the paper or revised it critically;
He/she must have given approval of the submitted and final versions.
Copyright Transfer Agreement: CellR4 Authors will be required to sign a Copyright Transfer Agreement (click to download PDF) for all papers accepted for publication. Signature of the CTA is a condition of publication and papers will not be passed to the publisher for production unless a signed form has been received. After submission, Authors cannot submit their manuscript to other journals. After acceptance, the Publisher got the rights and became the owner of the paper. To assist Authors, an appropriate CTA form will be supplied by the editorial office. The original completed Copyright Transfer Agreement must be signed by the corresponding Author and sent by e-mail to CellR4. The Editors retain the usual right to modify the style and length of a contribution (major changes being agreed with the corresponding Author) and to decide the time of publication.
Presentation of Manuscripts
A title page must contain the Authors’ names, appointments and place of work at the relevant time, plus the full contact details of the Corresponding Author including their current e-mail address. A full and a short running title should be given, together with a small number of keywords for indexing purposes.
The text should start with a structured Abstract, not exceeding 270 words, organized into sections using all of the following headings INTRODUCTION or BACKGROUND or OBJECTIVE, PATIENTS AND METHODS or MATERIALS AND METHODS, RESULTS, CONCLUSIONS. The paper should then proceed conventionally: Introduction or Background, Patients and Methods or Materials and Methods, Results, Discussion, Conclusions, and References. Pages should be numbered consecutively in Arabic numerals, including tables, figure legends (with magnifications if needed), acknowledgments and declaration of interests. Review Articles and Systematic Reviews also require a structured summary using all of the following headings: INTRODUCTION, PATIENTS AND METHODS or MATERIALS AND METHODS (e.g., search terms used), RESULTS (avoid vague statements e.g., ‘…will be discussed’), CONCLUSIONS (e.g., need for future studies).
References must be numbered in the order in which they are first mentioned in the text, and should be identified in the text, tables and legends by Arabic numbers in superscript. The US National Library of Medicine and used in Index Medicus applies (for more details see the section “References”). References must be verified by the Authors against the original documents.
Authors who want to publish on our Journal must follow the guidelines on Good Publication Practice: COPE https://publicationethics.org/resources/guidelines and PERK http://jp.elsevier.com/_old/editors/perk. These guidelines aim to ensure that articles are published in a responsible and ethical manner.
When reporting the reference numbers in the text, you must follow these rules: “1-2” must be written as “1,2” and so on. You have to put “-“ just in case you have many consecutive numbers. For example: “1,2,3,4,5,6” must be written as “1-6”;
References’ numbers must follow a chronological order within the text and must be inserted before the punctuation. (YES 12. NO.12)
Complete all the references in accordance with the Instructions for the authors (see How to submit an article, europeanreview.org): list all the authors (NOT et al), year without month of publication, delete the number of the single issue after the volume’s number, name of the journal: write the international acronyms without any punctuation; you must put a space after semicolon and colon (NOT 2014;2014:907915, YES 2014; 2014: 907915); moreover, initial and final pages must be entirely reported (NOT 135-46; YES 135-146). Delete the PMID and DOI number when you have the data aforementioned;
In the references, you must enter a space after semicolon and colon
- YES: Garcia-Contreras M, Brooks RW, Boccuzzi L, Robbins PD, Ricordi C. Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus. Eur Rev Med Pharmacol Sci 2017; 21: 2940-2956.
- NOT: Garcia-Contreras M, Brooks RW, Boccuzzi L, Robbins PD, Ricordi C. Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus. EurRevMedPharmacolSci 2017;21:2940-2956.
In the references, you must substitute “and” with “,” (comma) before the last author’s name;
In the references all the authors must be written with the same character size. You must write only the first letter in capital letter, without change the size of them.
(NOT) Example 1: DA. Baidal, C. Ricordi, M. Garcia-Contreras, A. Sonnino, A. Fabbri. Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: A potential role in preservation of beta-cell mass. Eur Rev Med Pharmacol Sci. 2016 Jul;20(15):3313-8.
(YES) Example 1: Baidal DA, Ricordi C, Garcia-Contreras M, Sonnino A, Fabbri A. Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: a potential role in preservation of beta-cell mass. Eur Rev Med Pharmacol Sci 2016; 20: 3313-3318.
(NOT) Example 2: Gomez-Meade C.A., Lopez-Mitnik G. V., Messiah S. E., Garcia-Contreras M., Sanchez J. Vitamin D status in children and adolescents with type 1 diabetes in a sun-rich environment. CellR4 2016; 4 (5): e2140
(YES) Example 2: Gomez-Meade CA, Lopez-Mitnik GV, Messiah SE, Garcia-Contreras M, Sanchez J. Vitamin D status in children and adolescents with type 1 diabetes in a sun-rich environment. CellR4 2016; 4: e2140.
Endnote’s template for CELLR4 formatting can be downloaded from the following link:
Figure legends should be included in the main text of the manuscript and not form part of the figures. For production purposes, it is best if you can supply figures in TIFF format; however, it is also possible to use Illustrator or Photoshop software saved in the ‘.eps’, ‘.tif’ or ‘.jpg’ format. If you are unable to provide these specified formats, please provide the figures in as many different files formats as soon as possible.
The figure resolution/specification for various types of original figures, at their final size, should be as follows: Line art – Minimum 600 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size. Halftone (i.e. both B/W and Colour photographs) – Minimum 300 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size. Line and tone (line art and halftone combined) – Minimum 600 dpi, measuring preferably 13 by 18 cm and no more than 20 by 25 cm in size.
For line figures, the lines should be solid, the text in a standard font and not blurred, and the overall image should be sharp and clear. Avoid using tints if possible; if they are essential to the understanding of the figure, try to make them coarse. As a guide, if the electronic files are viewed at 400% on the computer screen and they look blurred or pixelated in any way then they will NOT be of sufficient quality for printing.
Figure and table legends must be able to stand alone in the text and thus full descriptive legends for all figures and tables should be supplied.
Units and Abbreviations
All measurements should be in SI units with the exception of hemoglobin (g/dL) and blood pressure (mmHg). Original observations recorded in other units should be stated, together with the appropriate conversion factors. Standard abbreviations, without punctuation, are used. Units, Symbols and Abbreviations (1988) published by the Royal Society of Medicine, and SI: The International System of Units (1982) from HMSO both provide useful guides. Abbreviations, used sparingly, should follow the first full spelling, in parentheses. A list of abbreviations at the beginning of the article is accepted only if they are more than 8.
Methods should be referenced. Two-tailed significance tests should be used unless explicitly stated. Controls should be described as completely as experimental subjects. Measures of location should be accompanied by measures of variability (e.g. mean and confidence intervals) as well as conventional probability values. Clinical trial reports should include the power of the study design.
Ethics, Institutional Review Boards, and Informed Consent
Submitted clinical studies must include a reference to the appropriate Ethics Committee / Institutional Review Board (IRB) and have an appropriate Consent Form approved by the Ethics Committee / IRB before enrollment of the research subjects in the reported study. Appropriate review process and approval should be also documented for all pre-clinical experimental studies submitted. When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed. Should any questionable approval process emerge, the Editors reserve the right to reject any submitted paper.
All clinical trials submitted to CellR4 for consideration of publication must be registered http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial as “any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt.”http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial as “any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt.”
For definitions and further information, please see the section titled http://www.icmje.org/about-icmje/faqs/icmje-recommendations/ found in ICMJE’s Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Please note, however, that unlike ICMJE, CellR4 does not require trials to be registered before enrollment begins, although CellR4 does encourage this practice. When submitting your manuscript, please include the unique trial number and the name of the registry (e.g., ClinicalTrials.gov or ISRCTN) at the end of the abstract and in your cover letter.
Plagiarism or other types of unethical publication practice
About plagiarism or other types of unethical publication practice, we follow the COPE (https://publicationethics.org/resources/guidelines) and PERK (http://www.elsevier.com/editors/perk) guidelines.
On a practical level, the first thing we do is conduct an early investigation using our anti‐plagiarism software. Our Journal makes a plagiarism checker by a certificate program on all the articles. Also, articles that are related to the suspected case of plagiarism or other unethical practice are checked accuracy by either the reviewer feedback and observations or the Editors own observations. Our anti‐plagiarism software, however, will not identify “salami slicing”. So it is imperative that each case is looked at individually and, therefore, we do not advocate the use of one statement of actions to penalize the offender. Each case is considered separately and, as editors, we will need to decide if it is a deliberate action on the part of the author or it is due to lack of understanding of the requirements of ethical writing. This can happen for new authors or some authors where translation to English is often difficult. An example of this is where there are no words/phrases in that language that translate into English, and a developing practice that we noted is the ‘borrowing’ of words, phrases or often sentences that are considered appropriate for what authors mean to say.
CellR4 disapproves any kind of malpractice and unethical practice.
Sources of financial support during the last two years must be acknowledged. Please read the following statements, adding those sections, which are relevant at the end of your submitted manuscript under a heading ‘Statement of Interests’.
Authors’ declaration of personal interests: (i) [Name of individual] has served as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. (ii) [Name of individual] is an employee of [name of organization]. (iii) [Name of individual] owns stocks and shares in [name of organization]. (iv) [Name of individual] owns patent [patent identification and brief description].
Declaration of funding interests: (i) This study was funded [in part or in full] by [insert name of funding organization], grant number [insert grant or other identification number]. (ii) The [writing or preparation] of this paper was funded in part by [insert name of funding organization]. (iii) Initial data analyses were undertaken by [name of individuals if not listed as Authors] who are employees of [name company] and received funding from [insert name of funding organization]. (iv) Writing support was provided by [insert name of individual(s)] of [name company] and funded by [insert name of funding organization].
Generic names should, in general, be used. If an Author desires, brand names may be inserted in parentheses. Drug names are spelled out according to the European Pharmacopoeia, but the American spelling should be used after the first use of a drug name.
Revised articles must be submitted again within 2 months, or else will be considered as rejected.
The corresponding Author will receive an e-mail with a pdf file of the galley proof. The galley proof can be downloaded as a PDF (portable document format) file. Acrobat Reader will be required in order to read this file. This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Excessive changes (i.e. over 100 characters) made by the Author to the proofs, excluding typesetting errors, will be charged separately. Changes to figures and tables have an extra cost. Please check carefully the galley proof (especially for what concerns name of Authors, affiliations and corresponding Authors) as after its approval no further change will be possible.
Before the publication, CellR4 sends the final galley proof in which only missed misstatements in the previous galley proof can be corrected.
Paper reprints shall be charged. Electronic offprints are sent to the first Author at his/her first email address on the title page of the paper, on request. For this reason, please ensure that the name, address and email address of the corresponding Author are clearly indicated on the manuscript title page if he/she is not the first Author of the paper.
You can contact email@example.com
Our team will be able to provide advice and quotations for supplements.
Cost of Publication
Free of charge.